Sponsor:
Proteonomix, Inc.
Code:
NCT01711073
Conditions
End Stage Liver DIsease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Mobilization with G-CSF and Mozobil
Brief summary:
Conditions
End Stage Liver DIsease
Study ID
NCT01711073
Start date
Oct, 2012
Status verified date
Jan, 2013
Completion date
Sep, 2013
Anticipated
Primary completion date
Sep, 2013
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
15 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Mobilization with G-CSF plus Mozobil
Interventions
Mobilization with G-CSF and Mozobil
Primary outcome measure
Locations
University of Medicine and Dentistry of New Jersey
Recruiting
Newark, New Jersey, United States, 07101
Contacts
Baburao Koneru, MD
koneruba@umdnj.eduSponsor
Proteonomix, Inc.
Last update posted
Jan 24, 2013
Last verified
Jan, 2013
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Proteonomix, Inc. on 2013-01-24.